Summary:
Major ABO incompatibility in stem cell transplant recipients has been associated with pure red cell aplasia (PRCA). Reduction of incompatible isohaemagglutinin titres pre-transplant by various methods has been thought to reduce the incidence of PRCA. Our data suggest that pre-transplant reduction of incompatible isohaemagglutinin titres by donor group plasma infusion does not reduce the incidence of PRCA. We also failed to find any relationship between pre-transplant ABO isohaemagglutinin titre and the risk of developing PRCA.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Petz LD . Immunohematologic problems associated with bone marrow transplantation. Transfus Med Rev 1987; 1: 85–100.
Mielcarek M, Leisenring W, Tork-Storb B, Storb R . Graft versus host disease and donor directed haemagglutinin titres after ABO-mismatched related and unrelated marrow allografts: evidence for a graft versus plasma cell effect. Blood 2000; 96: 1150–1156.
Eastlund T . The histo-blood group ABO system and tissue transplantation. Transfusion 1998; 38: 975–988.
Stussi G, Seebach L, Muntwyler J et al. Graft versus host disease and survival after ABO incompatible allogeneic bone marrow transplantation: a single center experience. Br J Haematol 2001; 113: 251–253.
Bensinger WI, Buckner CD, Thomas ED et al. ABO incompatible marrow transplants. Transplantation 1982; 33: 427–429.
Mehta J, Powles R, Horton C et al. The relationship between donor recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA identical siblings. Bone Marrow Transplant 1995; 15: 853–858.
Sniecinski IJ, Olen L, Petz LD, Blume KG . Immunohaematologic consequences of major ABO mismatched bone marrow transplantation. Transplantation 1988; 45: 530–534.
Gmur JP, Burger J, Schaffner A et al. Pure red cell aplasia of long duration complicating major ABO incompatible bone marrow transplantation. Blood 1990; 75: 290–295.
Benjamin RJ, Connors JM, McGurk S et al. Prolonged erythroid aplasia after major ABO mismatched transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 1998; 4: 151–156.
Bar BM, Van Dijk BA, Schattenberg A et al. Erythrocyte repopulation after major ABO incompatible transplantation with lymphocyte depleted bone marrow. Bone Marrow Transplant 1995; 16: 793–799.
Lee JH, Lee KH, Kim S et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 179–184.
Bensinger WI, Buckner CD, Clift AR, Thomas ED . Plasma exchange and plasma modification for the removal of anti-red cell antibodies prior to ABO incompatible marrow transplant. J Clin Apheresis 1987; 3: 174–177.
Gale RP, Feig S, Ho W et al. ABO blood group system and bone marrow transplantation. Blood 1977; 50: 185–194.
Tichelli A, Gratwohl A, Wenger R et al. ABO incompatible bone marrow transplantation: in vivo adsorption, an old forgotten method. Transplant Proc 1987; 19: 4632–4637.
Stussi G, Muntwyler J, Passweg JR et al. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 87–93.
Buckner CD, Clift RA, Sanders JE et al. ABO incompatible marrow transplants. Transplantation 1978; 26: 233–238.
Bensinger WI, Buckner CD, Clift AR . Whole blood immuno adsorption of anti-A or anti-B antibodies. Vox Sang 1985; 48: 357–361.
Nussbaumer W, Kilga S, Thaler J et al. Prevention of acute hemolysis in transplanting ABO incompatible bone marrow. Onkologie 1991; 14: 117.
Weisneth M, Hertenstein B, Bunjes D et al. ABO incompatible bone marrow transplantation. Beitr Infusionther 1992; 30: 354–358.
Hocker P, Pittermann E . Plasma exchange in haematological disorders. J Wien Klin Wochenschr 1985; 3: 115–122.
Slave I, Urban C, Schwinger W et al. ABO incompatible bone marrow transplantation: prevention of hemolysis by alkaline hydration with mannitol diuresis in conjunction with red cell reduced buffy coat bone marrow. Wien Klin Wochenschr 1992; 104: 93–96.
Braine HG, Sensenbrenner LL, Wright SK et al. Bone marrow transplantation with major ABO blood group incompatibility using erythrocyte depletion of marrow prior to infusion. Blood 1982; 60: 420–425.
Dinsmore RE, Reich LM, Kapoor N et al. ABH incompatible bone marrow transplantation: removal of erythrocytes by starch sedimentation. Br J Haematol 1983; 54: 441–449.
Schanz U, Gmur J . Rapid and automated processing of bone marrow grafts without Ficoll density gradient for transplantation of cryopreserved autologous or ABO incompatible allogeneic bone marrow. Bone Marrow Transplant 1992; 10: 507–513.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Damodar, S., George, B., Mammen, J. et al. Pre-transplant reduction of isohaemagglutinin titres by donor group plasma infusion does not reduce the incidence of pure red cell aplasia in major ABO-mismatched transplants. Bone Marrow Transplant 36, 233–235 (2005). https://doi.org/10.1038/sj.bmt.1705031
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705031
Keywords
This article is cited by
-
Pre-transplant donor-type red cell transfusion is a safe and effective strategy to reduce isohemagglutinin titers and prevent donor marrow infusion reactions in major ABO-mismatched transplants
Annals of Hematology (2021)
-
Impact of ABO incompatibility on outcomes after haploidentical hematopoietic stem cell transplantation for severe aplastic anemia
Bone Marrow Transplantation (2020)